Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 11/20 | 0.72 |
| ▸ | PRMT6 | Q96LA8 | 11/20 | 0.72 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.72 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.72 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23972324 | 0.87 | CARM1 (0.67) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL6538340 | 0.84 | CARM1 (0.68) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL21253259 | 0.84 | CARM1 (0.68) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL11232221 | 0.84 | CTSL (0.55) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| Oxalic Acid SCHEMBL7316888 | 0.84 | BCHE (0.66) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL22854624 | 0.84 | CARM1 (1.00) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL5140977 | 0.83 | CARM1 (0.66) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL8551647 | 0.82 | SIGMAR1 (0.64) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL31705842 | 0.82 | CARM1 (0.64) | CARM1PRMT6PRMT8TMEM97SIGMAR1 | |
| SCHEMBL8646865 | 0.82 | CARM1 (0.64) | CARM1PRMT6PRMT8TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CARM1 150/4885PRMT6 133/4885PRMT8 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.